US 12,006,504 B2Granted

Production of DHA and other LC PUFAs in plants

AssigneesDsm IP Assets B.V., Dow AgroSciences LLC

InventorsTerence A. Walsh, Daniel Gachotte, Ann Owens Merlo, Paul G. Roessler, James George Metz, Scott Bevan, Jerry M. Kuner

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The invention provides recombinant host organisms (e.g., plants) genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins (e.g., PPTase and/or ACoAS) that allow for and/or improve the production of PUFAs in the host organism. The present invention also relates to methods of making and using such organisms (e.g., to obtain PUFAs) as well as products obtained from such organisms (e.g., oil and/or seed).

Claims15

Dependent claims

A method of obtaining a canola seed oil comprising the step of extracting a canola seed oil from a genetically modified Brassica plant, said genetically modified Brassica plant being genetically modified to express a PUFA synthase system derived from a eukaryotic source, the canola seed oil comprising at least 0.01% docosahexaenoic acid (DHA), wherein said canola seed oil is of the intermediate or side products of gamma-linolenic acid (GLA;

18:3, n-6), stearidonic acid (STA or SDA;
18:4, n-3), dihomo-gamma-linolenic acid (DGLA or HGLA;
20:3, n-6), arachidonic acid (ARA, C20:4, n-6), and eicosatrienoic acid (ETA;
20:3, n-9), so long as such intermediate or side products are not naturally produced by the endogenous FAS system in the wild-type canola plant.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 17/669,945Filed 11 Feb 2022 · continuation
Priority: 17 May 2010
Published: US 2022/0170037 A12 Jun 2022
Granted: 11 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification32 codes

C12N 15/8247
Involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine: involving modified lipid metabolism, e.g. seed…
A61P 1/04
Drugs for disorders of the alimentary tract or the digestive system: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of…
A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for liver or gallbladder disorders, e.g. hepatoprotective agents,…
A61P 3/00
Drugs for disorders of the metabolism

Family

Application61/345,537Us provisional application · filed 17 May 2010
PCT/US2011/036869Parent of this continuation · filed 17 May 2011
Application15/825,107Parent of this division · filed 29 Nov 2017
Application16/139,534Parent of this continuation · filed 24 Sep 2018
US 2022/0170037 A1Pre-grant publication · published 2 Jun 2022
US 10,669,554 B2Parent of this division
Application16/139,534Parent of this division
Application13/698,412Parent of this continuation
Application15/825,107Parent of this continuation
US 2013/0150599 A1Published application
US 2018/0073036 A1Published application
US 2019/0010510 A1Published application
US 12,006,504 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key